AstraZeneca (AZN) shared positive interim data from the ongoing SERENA-6 Phase 3 trail evaluating camizestrant and CDK4/6 inhibitors as a ...

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...

Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s ...

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ: AZN) stands against the other ...

AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer.

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

The phase 3 SERENA-6 study randomised patients with HR-positive, HER2-negative advanced breast cancer whose tumours had an ...

Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s (AZN) camizestrant in ...

AstraZeneca (NASDAQ:AZN) announced on Wednesday that its experimental breast cancer treatment, camizestrant, helped extend survival without disease progression in patients with an advanced form of the ...

Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...